Prognostic significance of NEK2 in human solid tumors: a systematic review and meta-analysis.

Haipeng Liu,Xichen Wang,Kang Chen,Xiao Chen,Zeping Huang,Lanning Yin

doi:10.1042/bsr20180618

Haipeng Liu, Xichen Wang + Show 4 more

Open Access

https://doi.org/10.1042/bsr20180618

Copy DOI

Journal: Bioscience reports	Publication Date: Jan 18, 2019
Citations: 3	License type: CC BY 4.0

Affiliation: Lanzhou University Second Hospital

Abstract

A consensus about the prognostic role of NIMA-related kinase 2 (NEK2) expression in various solid tumors has not been made yet. Thus, this meta-analysis aimed to systematically assess the prognostic role of NEK2 expression in patients with solid tumors. The eligible studies were identified through searching PubMed, Web of Science, and EMBASE. The hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) were used to evaluate the link between NEK2 overexpression and overall survival (OS) and disease-free survival/recurrence-free survival (DFS/RFS) of patients with solid tumors. A total of 17 studies with 4897 patients were included in this meta-analysis. Among these studies, all of them explored the association between NEK2 expression and OS of patients with solid tumors. Our pooled analysis indicated that NEK2 overexpression was significantly related to adverse OS (HR = 1.66; 95% CI: 1.38–2.00; P = 0.001). Additionally, there were six studies with 854 patients that investigated the association between NEK2 expression and DFS/RFS. Our pooled result indicated that there was a substantial relationship between NEK2 overexpression and poorer DFS/RFS (HR = 2.00; 95% CI: 1.61–2.48; P = 0.003). In conclusion, our meta-analysis indicated that NEK2 may be a useful predictor of prognosis and an effective therapeutic target in solid tumors. Nevertheless, more high-quality studies are warranted to further support our conclusions because of several limitations in our meta-analysis.

Highlights

Human solid tumors have been the main root of global mortality for many years and remains a worldwide health problem [1]
We found that never in mitosis (NIMA)-related kinase 2 (NEK2) overexpression was tightly related to worse overall survival (OS) of patients with hepatocellular carcinoma (HCC) (HR = 1.50; 95% confidence interval (CI): 1.18–1.91; P < 0.01), colorectal cancer (CRC) (HR = 2.03; 95% CI: 1.16–3.56; P = 0.03), glioma (HR = 3.15; 95% CI: 1.76–5.62; P < 0.01), lung cancer (HR = 2.04; 95% CI: 1.37–3.05; P < 0.01), breast cancer (HR = 1.52; 95% CI: 1.32–1.75; P < 0.01), and pancreatic duct adenocarcinoma (HR = 1.06; 95% CI: 1.01–1.12; P = 0.03) (Table 2)
Our combined results confirmed that there was a significant association between NEK2 overexpression and poor OS and disease-free survival (DFS)/recurrence-free survival (RFS) of patients with solid tumor, suggesting that NEK2 could be a useful prognostic predictor and a potential therapeutic target in patients with solid tumor

Summary

Introduction

Human solid tumors have been the main root of global mortality for many years and remains a worldwide health problem [1]. Clinicopathologic parameters that mainly include pathological grade and clinical stage are the main factors used to predict the prognosis of cancer patients. These factors do not often work as a reliable predictors of early diagnosis and individual prognosis, which imposes restriction on the efficiency of therapies for solid tumors. Many cell division-associated proteins are overexpressed in various cancers and contribute to the initiation of CIN in tumor cells [7,8]. There is evidence demonstrating that the c 2019 The Author(s)

Methods

Results

Conclusion